As a young, dynamic and creative molecular diagnostics company, we have specialized in simple and rapid solutions for the diagnosis of severe infectious diseases in hospitalized patients. We help to combat infections effectively and detect antibiotic resistance at an early stage.
Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
Curetis Expects Near-Term FDA Decision on De Novo Request
Reanimation Congress 2018 - Paris, France - 24 to 26 January, 2018
28. Symposium Intensivmedizin + Intensivpflege - Bremen, Germany - 14 to 16 February, 2018